SUGAMMADEX CAS No.343306-71-8
GMP ISO FDA
343306-71-8
Pharmaceutical grade
99%
Shanghai
JINLAN PHARM
25Kg/drum
2022-12-31
additives,pharmaceutical chemicals,organic intermediate,chemical intermediates,Pharmaceutical Intermediates,catalyst
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceSugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery in adults. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.
ChEBI: An octasaccharide derivative that is gamma-cyclodextrin in which all eight primary hydroxy groups are replaced by 2-(carboxyethyl)sulfanyl groups. Used (as the octasodium salt) for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery.CertificatesBasic Info-
Product Name:
SUGAMMADEX
Other Name:Shu Glucose;SUGAMMADEX;Org 25969;Sugammadex [inn];Unii-361lpm2T56;SugaMMadex SodiuM;Sugammagex;Bridion
CAS No.:343306-71-8
Molecular Formula:C72H112O48S8
InChIKeys:WHRODDIHRRDWEW-JLBXVEOTNA-N
Molecular Weight:2002.15
Exact Mass:2002.15
EC Number:253-874-2
Color/Form:White to Pale Beige
Categories:
Characteristics-
Density:
1.559±0.06 g/cm3(Predicted)
Melting Point:>208°C (dec.)
PKA:3.42±0.10(Predicted)
Critical Temperature & Pressure:Inert atmosphere,Room Temperature
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
additives,pharmaceutical chemicals,organic intermediate,chemical intermediates,Pharmaceutical Intermediates,catalyst
-
Location:
hangzhou,zhejiang
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
30 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2020
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
More from this Seller
-
-
-
Trametinib CAS No.871700-17-3
Pharmaceutical grade / 99%
-
-
-
-
PQ10 CAS No.81859-24-7
Pharmaceutical grade / 99%
-
-
-
-
Ruxolitinib CAS No.941678-49-5
Pharmaceutical grade / 99%
-
-
-
-
Guanfacine HCl CAS No.29110-48-3
Pharmaceutical grade / 99%
-
-
-
-
Glycerine CAS No.56-81-5
Pharmaceutical grade / 99%
-
-
-
-
Degarelix Acetate CAS No.214766-78-6
Pharmaceutical grade / 99%
-